Literature DB >> 15580304

Selectively frequent expression of CXCR5 enhances resistance to apoptosis in CD8(+)CD34(+) T cells from patients with T-cell-lineage acute lymphocytic leukemia.

Zhang Qiuping1, Xiong Jie, Jin Youxin, Wu Qun, Ju Wei, Liu Chun, Wang Jin, Liu Yan, Hu Chunsong, Yang Mingzhen, Gao Qingping, Li Qun, Zhang Kejian, Sun Zhimin, Liu Junyan, Tan Jinquan.   

Abstract

We investigated CD4(+)CD34(+), CD8(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells from cord blood and from typical patients with T-cell-lineage acute lymphocytic leukemia and T-cell-lineage chronic lymphocytic leukemia in terms of expression and functions of CXCR5/CXCL13. We found that CXCR5 was selectively frequently expressed on T-cell-lineage acute (chronic) lymphocytic leukemia (T-ALL) CD8(+)CD34(+) T cells, but not on T-ALL CD4(+)CD34(+), CD4(+)CD34(-), and CD8(+)CD34(-) T cells. CXCR5 was rarely expressed on all types of CD34(+) and CD34(-) CB or T-CLL T cells. CXCL13/B cells attracting chemokine 1 induced significant resistance to TNF-alpha-mediated apoptosis in T-ALL CD8(+)CD34(+) T cells, instead of induction of chemotactic and adhesive responsiveness. A proliferation-inducing ligand expression in T-ALL CD8(+)CD34(+) T cells was upregulated by CXCL13/BCA-1 (B-cell attracting chemokine 1). The CXCR5/CXCL13 pair by means of activation of APRIL (A proliferation-inducing ligand) induced resistance to apoptosis in T-ALL CD8(+)CD34(+) T cells in livin-dependent manner. In this process, cell-cell contact in culture was necessary. Based on our findings, we suggested that there were differential functions of CXCR5/CXCL13 in distinct types of cells. Normal lymphocytes, especially naive B and T cells, utilized CXCR5/CXCL13 for migration, homing, maturation, and cell homeostasis, as well as secondary lymphoid tissue organogenesis. Meanwhile, certain malignant cells took advantages of CXCR5/CXCL13 for infiltration, resistance to apoptosis, and inappropriate proliferation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15580304     DOI: 10.1038/sj.onc.1208184

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  6 in total

1.  Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia-reperfusion injury.

Authors:  Kengo Furuichi; Ji-Liang Gao; Richard Horuk; Takashi Wada; Shuichi Kaneko; Philip M Murphy
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

2.  The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma.

Authors:  Shu-Jyuan Chang; Chia-Te Chao; Aij-Lie Kwan; Chee-Yin Chai
Journal:  Pathol Oncol Res       Date:  2022-04-28       Impact factor: 2.874

3.  Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro.

Authors:  Qun Zhao; Hui Zhang; Yong Li; Jun Liu; Xiaojie Hu; Liqiao Fan
Journal:  J Exp Clin Cancer Res       Date:  2010-08-30

4.  Lack of chemokine signaling through CXCR5 causes increased mortality, ventricular dilatation and deranged matrix during cardiac pressure overload.

Authors:  Anne Waehre; Bente Halvorsen; Arne Yndestad; Cathrine Husberg; Ivar Sjaastad; Ståle Nygård; Christen P Dahl; M Shakil Ahmed; Alexandra V Finsen; Henrik Reims; William E Louch; Denise Hilfiker-Kleiner; Leif E Vinge; Borghild Roald; Håvard Attramadal; Martin Lipp; Lars Gullestad; Pål Aukrust; Geir Christensen
Journal:  PLoS One       Date:  2011-04-18       Impact factor: 3.240

5.  Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients.

Authors:  J Panse; K Friedrichs; A Marx; Y Hildebrandt; T Luetkens; K Barrels; C Horn; T Stahl; Y Cao; K Milde-Langosch; A Niendorf; N Kröger; S Wenzel; R Leuwer; C Bokemeyer; S Hegewisch-Becker; D Atanackovic
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

6.  Evidence of perturbed germinal center dynamics, but preserved antibody diversity, in end-stage renal disease.

Authors:  Kristian Assing; Christian Nielsen; Marianne Jakobsen; Alexandra Scholze; Mads Nybo; Grete Soerensen; Sussie Mortensen; Knud Vejen; Torben Barington; Claus Bistrup
Journal:  Immun Inflamm Dis       Date:  2016-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.